Endocrine Abstracts

Introduction: Surgery is the primary therapy in most acromelagic patients. When persistent disease is observed, adjuvant medical therapy is used. Pasireotide is a somatostatin analogue (SSA) not approved for acromegaly therapy yet, but with a potentially better response, given that it binds to four out of five somatostatin receptors.Materials and methods: We present the case of an acromegalic patient with resistance to many therapies and response to trea...